New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis

Autoimmunity

Volumn 49, Issue 7, 2016, Pages 435-450

  Karczewski, Jacek ^a   Dobrowolska, Agnieszka ^a   Rychlewska Hańczewska, Anna ^a   Adamski, Zygmunt ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

pathogenesis; Psoriasis; psoriatic arthritis; Th cells

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 25; INTERLEUKIN 26; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 9; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR GATA 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; BIOLOGICAL MARKER; CYTOKINE;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNOPATHOGENESIS; INTERFERON PRODUCTION; MACROPHAGE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PSORIASIS; PSORIATIC ARTHRITIS; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH22 CELL; TH9 CELL; ANIMAL; DISEASE PREDISPOSITION; GENE EXPRESSION REGULATION; HELPER CELL; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ARTHRITIS, PSORIATIC; BIOMARKERS; CYTOKINES; DISEASE SUSCEPTIBILITY; GENE EXPRESSION REGULATION; HUMANS; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; PSORIASIS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84962433677     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2016.1166214     Document Type: Review

References (253)

1. Burgdorf, W. C. H., G., Plewig, H. H., Wolff, and M., Landthaler. 2010. Psoriasis. In:Braun-Falco's Dermatology. Springer, Heidelberg
2. Nevitt, G. J., and P. E., Hutchinson. 1996. Psoriasis in the community:prevalence, severity and patients' beliefs and attitudes towards the disease. Br. J. Dermatol. 135:533–537
3. Danielsen, K., A. O., Olsen, T., Wilsgaard, and A. S., Furberg. 2013. Is the prevalence of psoriasis increasing? A 30 year follow-up of a population-based cohort. Br. J. Dermatol. 168:E1303–E1310
4. Christophers, E., 2001. Psoriasis–epidemiology and clinical spectrum. Clin. Exp. Dermatol. 26:314–320
5. Neimann, A. L., S. B., Porter, and J. M., Gelfand. 2006. The epidemiology of psoriasis. Expert Rev. Dermatol. 1:63–75
6. Elder, J. T., A. T., Bruce, J. E., Gudjonsson, et al. 2010. Molecular dissection of psoriasis:integrating genetics and biology. J. Invest. Dermatol. 130:1213–1226
7. Nestle, F. O., D. H., Kaplan, and J., Barker. 2009. Mechanisms of disease:psoriasis. N. Engl. J. Med. 361:496–509
8. Christensen, T. E., K. P., Callis, J., Papenfuss, et al. 2006. Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypes. J. Invest. Dermatol. 126:2397–2403
9. Moll, J. M., and V., Wright. 1973. Psoriatic arthritis. Sem. Arthritis Rheum. 3:55–78
10. Chandran, V., 2013. The genetics of psoriasis and psoriatic arthritis. Clin. Rev. Allergy Immunol. 44:149–156
11. Helliwell, P., and W., Taylor. 2005. Classification and diagnostic criteria for psoriatic arthritis. Ann. Rheum. Dis. 64 (Suppl 2):ii3–ii8
12. Gladman, D. D., C., Antoni, P., Mease, D. O., Clegg, and P., Nash. 2005. Psoriatic arthritis:epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis. 64:ii14–ii17
13. Veale, D. J., 2013. Psoriatic arthritis:recent progress in pathophysiology and drug development. Arthritis Res. Ther. 15:224
14. Wright, V., 1959. Psoriatic arthritis. A comparative study of rheumatoid arthritis, psoriasis, and arthritis associated with psoriasis. Arch. Dermatol. 80:27–35
15. Baker, H., 1966. Epidemiological aspects of psoriasis and arthritis. Br. J. Dermatol. 78:249–261
16. Veale, D. J., C., Ritchlin, and O., Fitzgerald. 2005. Immunopathology of psoriasis and psoriatic arthritis. Ann. Rheum. Dis. 64:ii26–ii29
17. Hébert, H. L., F. R., Ali, J., Bowes, et al. 2012. Genetic susceptibility to psoriasis and psoriatic arthritis:implications for therapy. Br. J. Dermatol. 166:474–482
18. Raychaudhuri, S. K., E., Maverakis, and S. P., Raychaudhuri. 2014. Diagnosis and classification of psoriasis. Autoimmun. Rev. 13:490–495
19. Sigurdardottir, S. L., R. H., Thorleifsdottir, H., Valdimarsson, and A., Johnston. 2013. The role of the palatine tonsils in the pathogenesis and treatment of psoriasis. Br. J. Dermatol. 168:237–242
20. Sigurdardottir, S. L., R. H., Thorleifsdottir, H., Valdimarsson, and A., Johnston. 2013. The association of sore throat and psoriasis might be explained by histologically distinctive tonsils and increased expression of skin-homing molecules by tonsil T cells. Clin. Exp. Immunol. 174:139–151
21. Nickoloff, B. J., and T., Wrone-Smith. 1999. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am. J. Pathol. 155:145–158
22. Telfer, N. R., R. J., Chalmers, K., Whale, and G., Colman. 1992. The role of streptococcal infection in the initiation of guttate psoriasis. Arch. Dermatol. 128:39–42
23. Prinz, J. C., 2004. Disease mimicry–a pathogenetic concept for T cell-mediated autoimmune disorders triggered by molecular mimicry? Autoimmun. Rev. 3:10–15
24. Prinz, J. C., 2001. Psoriasis vulgaris–a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin. Exp. Dermatol. 26:326–332
25. Besgen, P., P., Trommler, S., Vollmer, and J. C., Prinz. 2010. Ezrin, maspin, peroxiredoxin 2, and heat shock protein 27:potential targets of a streptococcal-induced autoimmune response in psoriasis. J. Immunol. 184:5392–5402
26. Cai, Y., C., Fleming, and J., Yan. 2012. New insights of T cells in the pathogenesis of psoriasis. Cell. Mol. Immunol. 9:302–309
27. Lande, R., E., Botti, C., Jandus, et al. 2014. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat. Commun. 5:5621
28. Zanetti, M., 2004. Cathelicidins, multifunctional peptides of the innate immunity. J. Leukoc. Biol. 75:39–48
29. Lande, R., J., Gregorio, V., Facchinetti, et al. 2007. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 449:564–569
30. Naldi, L., L., Chatenoud, D., Linder, et al. 2005. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis:results from an Italian case-control study. J. Invest. Dermatol. 125:61–67
31. Gaston, L., J. C., Crombez, M., Lassonde, et al. 1991. Psychological stress and psoriasis:experimental and prospective correlational studies. Acta Derm. Venerol. Suppl 156:37–43
32. Farber, E. M., B. J., Nickoloff, B., Recht, and J. E., Fraki. 1986. Stress, symmetry, and psoriasis:possible role of neuropeptides. J. Am. Acad. Dermatol. 14:305–311
33. Saraceno, R., C. E., Kleyn, G., Terenghi, and C. E., Griffiths. 2006. The role of neuropeptides in psoriasis. Br. J. Dermatol. 155:876–882
34. Girolomoni, G., and R. E., Tigelaar. 1990. Capsaicin-sensitive primary sensory neurons are potent modulators of murine delayed-type hypersensitivity reactions. J. Immunol. 145:1105–1112
35. Raychaudhuri, S. P., W. Y., Jiang, and S. K., Raychaudhuri. 2008. Revisiting the Koebner phenomenon:role of NGF and its receptor system in the pathogenesis of psoriasis. Am. J. Pathol. 172:961–971
36. Jiang, W. Y., S. P., Raychaudhuri, and E. M., Farber. 1998. Double-labeled immunofluorescence study of cutaneous nerves in psoriasis. Int. J. Dermatol. 37:572–574
37. Harvima, I. T., H., Viinamäki, A., Naukkarinen, et al. 1993. Association of cutaneous mast cells and sensory nerves with psychic stress in psoriasis. Psychother. Psychosom. 60:168–176
38. Raychaudhuri, S. P., M., Sanyal, H., Weltman, and S., Kundu-Raychaudhuri. 2004. K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis:an in vivo study using the severe combined immunodeficient mouse-human skin model. J. Invest. Dermatol. 122:812–819
39. Raychaudhuri, S. P., S. K., Raychaudhuri, K. R., Atkuri, et al. 2011. Nerve growth factor:a key local regulator in the pathogenesis of inflammatory arthritis. Arthritis Rheum. 63:3243–3252
40. Pincelli, C., 2000. Nerve growth factor and keratinocytes:a role in psoriasis. Eur. J. Dermatol. 10:85–90
41. Ciocon, D. H., and A. B., Kimball. 2007. Psoriasis and psoriatic arthritis:separate or one and the same? Br. J. Dermatol. 157:850–860
42. Fitzgerald, O., and M., Dougados. 2006. Psoriatic arthritis:one or more diseases? Best Pract. Res. Clin. Rheumatol. 20:435–450
43. Robinson, D. J., M., Hackett, J., Wong, et al. 2006. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders:an exploration using US healthcare claims data, 2001-2002. Curr. Med. Res. Opin. 22:989–1000
44. Ghoreschi, K., C., Weigert, and M., Röcken. 2007. Immunopathogenesis and role of T cells in psoriasis. Clin. Dermatol. 25:574–580
45. Chaudhari, U., P., Romano, L. D., Mulcahy, et al. 2001. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis:a randomised trial. Lancet. 357:1842–1847
46. Leonardi, C. L., J. L., Powers, R. T., Matheson, et al. 2003. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349:2014–2022
47. Schlaak, J. F., M., Buslau, W., Jochum, et al. 1994. T cells involved in psoriasis vulgaris belong to the Th1 subset. J. Invest. Dermatol. 102:145–149
48. Partsch, G., E., Wagner, B. F., Leeb, et al. 1998. T cell derived cytokines in psoriatic arthritis synovial fluids. Ann. Rheum. Dis. 57:691–693
49. Lew, W., A. M., Bowcock, and J. G., Krueger. 2004. Psoriasis vulgaris:cutaneous lymphoid tissue supports T-cell activation and “Type 1” inflammatory gene expression. Trends Immunol. 25:295–305
50. Victor, F. C., A. B., Gottlieb, and A., Menter. 2003. Changing paradigms in dermatology:tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin. Dermatol. 21:392–397
51. Jiang, S., 2011. Th17 cells in Health and Disease. Springer Science + Business Media, LLC, New York
52. Martin, D. A., J. E., Towne, G., Kricorian, et al. 2013. The emerging role of IL-17 in the pathogenesis of psoriasis:preclinical and clinical findings. J. Invest. Dermatol. 133:17–26
53. Weaver, C. T., R. D., Hatton, P. R., Mangan, and L. E., Harrington. 2007. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Ann. Rev. Immunol. 25:821–852
54. Acosta-Rodriguez, E. V., G., Napolitani, A., Lanzavecchia, and F., Sallusto. 2007. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8:942–949
55. Yang, L., D. E., Anderson, C., Baecher-Allan, et al. 2008. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature. 454:350–352
56. Yao, Z., S. L., Painter, W. C., Fanslow, et al. 1995. Human IL-17:a novel cytokine derived from T cells. J. Immunol. 155:5483–5486
57. Awasthi, A., L., Riol-Blanco, A., Jäger, et al. 2009. Cutting edge:IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells. J. Immunol. 182:5904–5908
58. Ciric, B., M., El-behi, R., Cabrera, et al. 2009. IL-23 drives pathogenic IL-17-producing CD8+ T cells. J. Immunol. 182:5296–5305
59. Sutton, C. E., S. J., Lalor, C. M., Sweeney, et al. 2009. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity. 31:331–341
60. Volpe, E., N., Servant, R., Zollinger, et al. 2008. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat. Immunol. 9:650–657
61. McGeachy, M. J., Y., Chen, C. M., Tato, et al. 2009. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat. Immunol. 10:314–324
62. Raphael, I., S., Nalawade, T. N., Eagar, and T. G., Forsthuber. 2014. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 74:5–17
63. Benedetti, G., and P., Miossec. 2014. Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. Eur. J. Immunol. 44:339–347
64. Lewis, B. J., S., Rajpara, A. M., Haggart, et al. 2013. Predominance of activated, clonally expanded T helper type 17 cells within the CD4+ T cell population in psoriatic lesions. Clin. Exp. Immunol. 173:38–46
65. Cai, Y., X., Shen, C., Ding, et al. 2011. Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity. 35:596–610
66. Lowes, M. A., T., Kikuchi, J., Fuentes-Duculan, et al. 2008. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 128:1207–1211
67. Zaba, L. C., M., Suárez-Fariñas, J., Fuentes-Duculan, et al. 2009. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J. Allergy Clin. Immunol. 124:1022–1130
68. Singh, T. P., M. P., Schön, K., Wallbrecht, et al. 2010. 8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J. Immunol. 184:7257–7267
69. Langley, R. G., B. E., Elewski, M., Lebwohl, et al. 2014. Secukinumab in plaque psoriasis–results of two phase 3 trials. N. Engl. J. Med. 371:326–338
70. McInnes, I. B., J., Sieper, J., Braun, et al. 2014. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis:a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann. Rheum. Dis. 73:349–356
71. O'Rielly, D. D., and P., Rahman. 2014. Genetics of psoriatic arthritis. Best Pract. Res. Clin. Rheumatol. 28:673–685
72. Yao, Z., M. K., Spriggs, J. M., Derry, et al. 1997. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine. 9:794–800
73. Honorati, M. C., R., Meliconi, L., Pulsatelli, et al. 2001. High in vivo expression of interleukin-17 receptor in synovial endothelial cells and chondrocytes from arthritis patients. Rheumatology (Oxford). 40:522–527
74. Harper, E. G., C., Guo, H., Rizzo, et al. 2009. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo:implications for psoriasis pathogenesis. J. Invest. Dermatol. 129:2175–2183
75. Homey, B., M. C., Dieu-Nosjean, A., Wiesenborn, et al. 2000. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J. Immunol. 164:6621–6632
76. Nograles, K. E., L. C., Zaba, E., Guttman-Yassky, et al. 2008. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 159:1092–1102
77. Liang, S. C., X. Y., Tan, D. P., Luxenberg, et al. 2006. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203:2271–2279
78. Gutowska-Owsiak, D., A. L., Schaupp, M., Salimi, et al. 2012. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp. Dermatol. 21:104–110
79. Dong, W., and P., Zhu. 2012. Functional niche of inflamed synovium for Th17-cell expansion and activation in rheumatoid arthritis:implication to clinical therapeutics. Autoimmun. Rev. 11:844–851
80. Hüffmeier, U., S., Uebe, A. B., Ekici, et al. 2010. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat. Genet. 42:996–999
81. Filer, C., P., Ho, R. L., Smith, et al. 2008. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum. 58:3705–3709
82. Bowes, J., G., Orozco, E., Flynn, et al. 2011. Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Ann. Rheum. Dis. 70:1641–1644
83. Eirís, N., L., González-Lara, J., Santos-Juanes, et al. 2014. Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus. J. Dermatol. Sci. 75:167–172
84. Kirkham, B. W., A., Kavanaugh, and K., Reich. 2014. Interleukin-17A:a unique pathway in immune-mediated diseases:psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 141:133–142
85. Raychaudhuri, S. P., S. K., Raychaudhuri, and M. C., Genovese. 2012. IL-17 receptor and its functional significance in psoriatic arthritis. Mol. Cell. Biochem. 359:419–429
86. Noordenbos, T., N., Yeremenko, I., Gofita, et al. 2012. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 64:99–109
87. Page, G., S., Lebecque, and P., Miossec. 2002. Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ:correlation with selective chemokine expression in rheumatoid synovium. J. Immunol. 168:5333–5334
88. Egan, P. J., A., van Nieuwenhuijze, I. K., Campbell, and I. P., Wicks. 2008. Promotion of the local differentiation of murine Th17 cells by synovial macrophages during acute inflammatory arthritis. Arthritis Rheum. 58:3720–3729
89. Rampersad, R. R., T. K., Tarrant, C. T., Vallanat, et al. 2011. Enhanced Th17-cell responses render CCR2-deficient mice more susceptible for autoimmune arthritis. PLoS One 6:e25833
90. Bartok, B., and G. S., Firestein. 2010. Fibroblast-like synoviocytes:key effector cells in rheumatoid arthritis. Immunol. Rev. 233:233–255
91. Ospelt, C., K. A., Reedquist, S., Gay, and P. P., Tak. 2011. Inflammatory memories:is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis? Autoimmun. Rev. 10:519–524
92. Jovanovic, D. V., J. A., Di Battista, J., Martel-Pelletier, et al. 1998. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J. Immunol. 160:3513–3521
93. Hwang, S. Y., J. Y., Kim, K. W., Kim, et al. 2004. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways. Arthritis Res. Ther. 6:R120–R128
94. Katz, Y., O., Nadiv, and Y., Beer. 2001. Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1,6, and 8 in skin and synovial fibroblasts:a possible role as a “fine-tuning cytokine” in inflammation processes. Arthritis Rheum. 44:2176–2184
95. Shahrara, S., S. R., Pickens, A. M., Mandelin, et al. 2010. IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J. Immunol. 184:4479–4487
96. Shahrara, S., S. R., Pickens, A., Dorfleutner, and R. M., Pope. 2009. IL-17 induces monocyte migration in rheumatoid arthritis. J. Immunol. 182:3884–3891
97. Moran, E. M., M., Connolly, W., Gao, et al. 2011. Interleukin-17A induction of angiogenesis, cell migration, and cytoskeletal rearrangement. Arthritis Rheum. 63:3263–3273
98. Van Bezooijen, R. L., L., Van Der Wee-Pals, S. E., Papapoulos, and C. W., Löwik. 2002. Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann. Rheum. Dis. 61:870–876
99. Koshy, P. J., N., Henderson, C., Logan, et al. 2002. Interleukin 17 induces cartilage collagen breakdown:novel synergistic effects in combination with proinflammatory cytokines. Ann. Rheum. Dis. 61:704–713
100. Moran, E. M., R., Mullan, J., McCormick, et al. 2009. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation:synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res. Ther. 11:r113
101. Sato, K., A., Suematsu, K., Okamoto, et al. 2006. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203:2673–2682
102. Pöllinger, B., T., Junt, B., Metzler, et al. 2011. Th17 cells, not IL-17 + γδ T cells, drive arthritic bone destruction in mice and humans. J. Immunol. 186:2602–2612
103. Kotake, S., N., Udagawa, N., Takahashi, et al. 1999. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103:1345–1352
104. Lubberts, E., L., van den Bersselaar, B., Oppers-Walgreen, et al. 2003. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J. Immunol. 170:2655–2662
105. Braun, T., and J., Zwerina. 2011. Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res. Ther. 13:235
106. Takagi, R., T., Higashi, K., Hashimoto, et al. 2008. B cell chemoattractant CXCL13 is preferentially expressed by human Th17 cell clones. J. Immunol. 181:186–189
107. Mitsdoerffer, M., Y., Lee, A., Jäger, et al. 2010. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc. Natl. Acad. Sci. USA. 107:14292–14297
108. Nakken, B., L. A., Munthe, Y. T., Konttinen, et al. 2011. B-cells and their targeting in rheumatoid arthritis–current concepts and future perspectives. Autoimmun. Rev. 11:28–34
109. Chiricozzi, A., E., Guttman-Yassky, M., Suárez-Fariñas, et al. 2011. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J. Invest. Dermatol. 131:677–687
110. Hartupee, J., C., Liu, M., Novotny, et al. 2007. IL-17 enhances chemokine gene expression through mRNA stabilization. J. Immunol. 179:4135–4141
111. Sun, D., M., Novotny, K., Bulek, et al. 2011. Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). Nat. Immunol. 12:853–860
112. Suárez-Fariñas, M., K., Li, J., Fuentes-Duculan, et al. 2012. Expanding the psoriasis disease profile:interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J. Invest. Dermatol. 132:2552–2564
113. Bettelli, E., Y., Carrier, W., Gao, et al. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 441:235–238
114. Raychaudhuri, S. P., 2013. Role of IL-17 in psoriasis and psoriatic arthritis. Clin. Rev. Allergy Immunol. 44:183–193
115. Apostolidis, S. A., L. A., Lieberman, K., Kis-Toth, et al. 2011. The dysregulation of cytokine networks in systemic lupus erythematosus. J. Interferon Cytokine Res. 31:769–779
116. Tu, E., D. K., Ang, S. A., Bellingham, et al. 2012. Both IFN-γ and IL-17 are required for the development of severe autoimmune gastritis. Eur. J. Immunol. 42:2574–2583
117. Ambrosi, A., A., Espinosa, and M., Wahren-Herlenius. 2012. IL-17:a new actor in IFN-driven systemic autoimmune diseases. Eur. J. Immunol. 42:2274–2284
118. Kryczek, I., A. T., Bruce, J. E., Gudjonsson, et al. 2008. Induction of IL-17+ T cell trafficking and development by IFN-gamma:mechanism and pathological relevance in psoriasis. J. Immunol. 181:4733–4741
119. Hirota, K., J. H., Duarte, M., Veldhoen, et al. 2011. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat. Immunol. 12:255–263
120. Nistala, K., S., Adams, H., Cambrook, et al. 2010. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc. Natl. Acad. Sci. USA. 107:14751–14756
121. Res, P. C., G., Piskin, O. J., de Boer, et al. 2010. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One. 5:e14108
122. Benham, H., P., Norris, J., Goodall, et al. 2013. Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res. Ther. 15:R136
123. Johnston, A., and J. E., Gudjonson. 2014. 22 again:IL-22 as a risk gene and important mediator in psoriasis. J. Invest. Dermatol. 134:1501–1503
124. Eyerich, S., K., Eyerich, D., Pennino, et al. 2009. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J. Clin. Invest. 119:3573–3585
125. Trifari, S., C. D., Kaplan, E. H., Tran, et al. 2009. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol. 10:864–871
126. Duhen, T., R., Geiger, D., Jarrossay, et al. 2009. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat. Immunol. 10:857–863
127. Yang, X., and S. G., Zheng. 2014. Interleukin-22:a likely target for treatment of autoimmune diseases. Autoimmun. Rev. 13:615–620
128. Boniface, K., F. X., Bernard, M., Garcia, et al. 2005. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J. Immunol. 174:3695–3702
129. Kagami, S., H. L., Rizzo, J. J., Lee, et al. 2010. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J. Invest. Dermatol. 2010:1373–1383
130. Caproni, M., E., Antiga, L., Melani, et al. 2009. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis:a randomized-controlled trial. J. Clin. Immunol. 29:210–214
131. Lo, Y. H., K., Torii, C., Saito, et al. 2010. Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. J. Dermatol. Sci. 58:225–227
132. Meephansan, J., K., Ruchusatsawat, W., Sindhupak, et al. 2011. Effect of methotrexate on serum levels of IL-22 in patients with psoriasis. Eur. J. Dermatol. 21:501–504
133. Fiocco, U., P., Sfriso, F., Oliviero, et al. 2010. Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint. Arthritis Res. Ther. 12:R148
134. Mitra, A., S. K., Raychaudhuri, and S. P., Raychaudhuri. 2012. Functional role of IL-22 in psoriatic arthritis. Arthritis Res. Ther. 14:R65
135. Zhang, L., Y. G., Li, Y. H., Li, et al. 2012. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One. 7:e31000
136. Raychaudhuri, S. K., A., Saxena, and S. P., Raychaudhuri. 2015. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin. Rheumatol. 34:1019–1023
137. Duffin, K. C., I. C., Freeny, S. J., Schrodi, et al. 2009. Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking. J. Invest. Dermatol. 129:2777–2783
138. Eder, L., V., Chandran, F., Pellett, et al. 2011. IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients. Ann. Rheum. Dis. 70:1594–1598
139. Hart, P. H., M., Ahern, M. D., Smith, and J. J., Finlay-Jones. 1995. Regulatory effects of IL-13 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis. Clin. Exp. Immunol. 99:331–337
140. Bessis, N., M. C., Boissier, P., Ferrara, et al. 1996. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur. J. Immunol. 26:2399–2403
141. Abrams, J. R., S. L., Kelley, E., Hayes, et al. 2000. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J. Exp. Med. 192:681–694
142. Zaba, L. C., I., Cardinale, P., Gilleaudeau, et al. 2007. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 204:3183–3194
143. Suárez-Fariñas, M., J., Fuentes-Duculan, M. A., Lowes, and J. G., Krueger. 2011. Resolved psoriasis lesions retain expression of a subset of disease-related genes. J. Invest. Dermatol. 131:391–400
144. Cheuk, S., M., Wikén, L., Blomqvist, et al. 2014. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J. Immunol. 192:3111–3120
145. Mackay, L. K., T. S., Angus, J. Z., Ma, et al. 2012. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc. Natl. Acad. Sci. USA. 109:7037–7042
146. Casey, K. A., K. A., Fraser, J. M., Schenkel, et al. 2012. Antigen-independent differentiation and maintenance of effector-like resident memory T cells in tissues. J. Immunol. 188:4866–4875
147. Jiang, X., R. A., Clark, L., Liu, et al. 2012. Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity. Nature. 483:227–231
148. Gershon, R. K., 1975. A disquisition on suppressor T cells. Transplant. Rev. 26:170–185
149. Sakaguchi, S., M., Miyara, C. M., Costantino, and D. A., Hafler. 2010. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10:490–500
150. Cosmi, L., F., Liotta, E., Lazzeri, et al. 2003. Human CD8 + CD25+ thymocytes share phenotypic and functional features with CD4 + CD25+ regulatory thymocytes. Blood. 102:4107–4114
151. Roncarolo, M. G., R., Bacchetta, C., Bordignon, et al. 2001. Type 1 T regulatory cells. Immunol. Rev. 182:68–79
152. Weiner, H. L., 2001. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol. Rev. 182:207–214
153. Kessel, A., T., Haj, R., Peri, et al. 2012. Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun. Rev. 11:670–677
154. Sakaguchi, S., T., Yamaguchi, T., Nomura, and M., Ono. 2008. Regulatory T cells and immune tolerance. Cell. 133:775–787
155. Baecher-Allan, C., J. A., Brown, G. J., Freeman, and D. A., Hafler. 2001. CD4 + CD25high regulatory cells in human peripheral blood. J. Immunol. 167:1245–1253
156. Fontenot, J. D., and A. Y., Rudensky. 2005. A well adapted regulatory contrivance:regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol. 6:331–337
157. Baron, U., S., Floess, G., Wieczorek, et al. 2007. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur. J. Immunol. 37:2378–2389
158. Ohkura, N., Y., Kitagawa, and S., Sakaguchi. 2013. Development and maintenance of regulatory T cells. Immunity. 38:414–423
159. Randolph, D. A., and C. G., Fathman. 2006. Cd4 + Cd25+ regulatory T cells and their therapeutic potential. Annu. Rev. Med. 57:381–402
160. Vignali, D. A., 2008. How regulatory T cells work. Nat. Rev. Immunol. 8:523–532
161. Tang, Q., and J. A., Bluestone. 2008. The FOXP3 + regulatory T cell:a jack of all trades, master of regulation. Nat. Immunol. 9:239–244
162. Allan, S. E., S. Q., Crome, N. K., Crellin, et al. 2007. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol. 19:345–354
163. Miyara, M., Y., Yoshioka, A., Kitoh, et al. 2009. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 30:899–911
164. Bach, J. F., 2003. Regulatory T cells under scrutiny. Nat. Rev. Immunol. 3:189–198
165. Horwitz, D. A., S. G., Zheng, and J. D., Gray. 2008. Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol. 29:429–435
166. Kleinewietfeld, M., F., Puentes, G., Borsellino, et al. 2005. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4 + T-cell subset. Blood. 105:2877–2886
167. Borsellino, G., M., Kleinewietfeld, D., Di Mitri, et al. 2007. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells:hydrolysis of extracellular ATP and immune suppression. Blood. 110:1225–1232
168. Baecher-Allan, C., E., Wolf, and D. A., Hafler. 2006. MHC class II expression identifies functionally distinct human regulatory T cells. J. Immunol. 176:4622–4631
169. Haas, J., B., Fritzsching, P., Trübswetter, et al. 2007. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J. Immunol. 179:1322–1330
170. Fritzsching, B., N., Oberle, E., Pauly, et al. 2006. Naive regulatory T cells:a novel subpopulation defined by resistance toward CD95L-mediated cell death. Blood. 108:3371–3378
171. Solstad, T., S. J., Bains, J., Landskron, et al. 2011. CD147 (Basigin/Emmprin) identifies FoxP3 + CD45RO + CTLA4+-activated human regulatory T cells. Blood. 118:5141–5151
172. Ito, T., S., Hanabuchi, Y. H., Wang, et al. 2008. Two functional subsets of FOXP3 + regulatory T cells in human thymus and periphery. Immunity. 28:870–880
173. Huehn, J., K., Siegmund, and A., Hamann. 2005. Migration rules:functional properties of naive and effector/memory-like regulatory T cell subsets. Curr. Top. Microbiol. Immunol. 293:89–114
174. Sather, B. D., P., Treuting, N., Perdue, et al. 2007. Altering the distribution of Foxp3(+) regulatory T cells results in tissue-specific inflammatory disease. J. Exp. Med. 204:1335–1347
175. Hirahara, K., L., Liu, R. A., Clark, et al. 2006. The majority of human peripheral blood CD4 + CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors. J. Immunol. 177:4488–7794
176. Sanchez Rodriguez, R., M. L., Pauli, I. M., Neuhaus, et al. 2014. Memory regulatory T cells reside in human skin. J. Clin. Invest. 124:1027–1036
177. Bernard, B. A., 2012. The human hair follicle, a bistable organ? Exp. Dermatol. 2:401–403
178. Lange-Asschenfeldt, B., D., Marenbach, C., Lang, et al. 2011. Distribution of bacteria in the epidermal layers and hair follicles of the human skin. Skin Pharmacol. Physiol. 24:305–311
179. Chang, C. Y., H. A., Pasolli, E. G., Giannopoulou, et al. 2013. NFIB is a governor of epithelial-melanocyte stem cell behaviour in a shared niche. Nature. 495:98–102
180. Gilhar, A., A., Etzioni, and R., Paus. 2012. Alopecia areata. N. Engl. J. Med. 366:1515–1525
181. Petukhova, L., M., Duvic, M., Hordinsky, et al. 2010. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 466:113–117
182. Pan, F., H., Yu, E. V., Dang, et al. 2009. Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science. 325:1142–1146
183. Sakaguchi, S., K., Wing, Y., Onishi, et al. 2009. Regulatory T cells:how do they suppress immune responses? Int. Immunol. 21:1105–1111
184. Conteduca, G., A., Rossi, F., Megiorni, et al. 2014. Single nucleotide polymorphisms in the promoter regions of Foxp3 and ICOSLG genes are associated with Alopecia areata. Clin. Exp. Med. 14:91–97
185. Buckner, J. H., 2010. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat. Rev. Immunol. 10:849–859
186. Sugiyama, H., R., Gyulai, E., Toichi, et al. 2005. Dysfunctional blood and target tissue CD4 + CD25high regulatory T cells in psoriasis:mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol. 174:164–173
187. Richetta, A. G., C., Mattozzi, M., Salvi, et al. 2011. CD4+ CD25 + T-regulatory cells in psoriasis. Correlation between their numbers and biologics-induced clinical improvement. Eur. J. Dermatol. 21:344–348
188. Yan, K. X., X., Fang, L., Han, et al. 2010. Foxp3+ regulatory T cells and related cytokines differentially expressed in plaque vs. guttate psoriasis vulgaris. Br. J. Dermatol. 163:48–56
189. Quaglino, P., M., Ortoncelli, A., Comessatti, et al. 2009. Circulating CD4 + CD25 bright FOXP3+ T cells are up-regulated by biological therapies and correlate with the clinical response in psoriasis patients. Dermatology. 219:250–258
190. Bovenschen, H. J., I. M., van Vlijmen-Willems, P. C., van de Kerkhof, and P. E., van Erp. 2006. Identification of lesional CD4+ CD25+ Foxp3+ regulatory T cells in Psoriasis. Dermatology. 213:111–117
191. Zhang, L., X. Q., Yang, J., Cheng, et al. 2010. Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity. Clin. Immunol. 135:108–117
192. Wang, H., T., Peters, A., Sindrilaru, et al. 2008. TGF-beta-dependent suppressive function of Tregs requires wild-type levels of CD18 in a mouse model of psoriasis. J. Clin. Invest. 118:2629–2639
193. Goodman, W. A., A. D., Levine, J. V., Massari, et al. 2009. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J. Immunol. 183:3170–3176
194. Clark, R. A., 2010. Skin resident T cells:the ups and downs of on site immunity. J. Invest. Dermatol. 130:362–370
195. Goodman, W. A., A. B., Young, T. S., McCormick, et al. 2011. Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J. Immunol. 186:3336–3345
196. Harris, T. J., J. F., Grosso, H. R., Yen, et al. 2007. Cutting edge:an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J. Immunol. 179:4313–4317
197. Bovenschen, H. J., P. C., van de Kerkhof, P. E., van Erp, et al. 2011. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J. Invest. Dermatol. 131:1850–1860
198. Miyara, M., G., Gorochov, M., Ehrenstein, et al. 2011. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun. Rev. 10:744–755
199. Ryder, L. R., E. M., Bartels, A., Woetmann, et al. 2012. FoxP3 mRNA splice forms in synovial CD4+ T cells in rheumatoid arthritis and psoriatic arthritis. APMIS. 120:387–396
200. Krejsgaard, T., L. M., Gjerdrum, E., Ralfkiaer, et al. 2008. Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome. Leukemia. 22:2230–2239
201. Bettelli, E., M., Dastrange, and M., Oukka. 2005. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc. Natl. Acad. Sci. USA. 102:5138–5143
202. Du, J., C., Huang, B., Zhou, and S. F., Ziegler. 2008. Isoform-specific inhibition of ROR alpha-mediated transcriptional activation by human FOXP3. J. Immunol. 180:4785–4793
203. Zikherman, J., and A., Weiss. 2008. Alternative splicing of CD45:the tip of the iceberg. Immunity. 29:839–841
204. Grigoryev, Y. A., S. M., Kurian, A. A., Nakorchevskiy, et al. 2009. Genome-wide analysis of immune activation in human T and B cells reveals distinct classes of alternatively spliced genes. PLoS One. 4:e7906
205. Ip, J. Y., A., Tong, Q., Pan, et al. 2007. Global analysis of alternative splicing during T-cell activation. RNA. 13:563–572
206. Heyd, F., G., ten Dam, and T., Möröy. 2006. Auxiliary splice factor U2AF26 and transcription factor Gfi1 cooperate directly in regulating CD45 alternative splicing. Nat. Immunol. 7:859–867
207. Lettesjö, H., E., Nordström, H., Ström, et al. 1998. Synovial fluid cytokines in patients with rheumatoid arthritis or other arthritic lesions. Scand. J. Immunol. 48:286–292
208. Burska, A., M., Boissinot, and F., Ponchel. 2014. Cytokines as biomarkers in rheumatoid arthritis. Mediat. Inflamm. 2014:545493
209. Aerts, N. E., E. J., Dombrecht, D. G., Ebo, et al. 2008. Activated T cells complicate the identification of regulatory T cells in rheumatoid arthritis. Cell. Immunol. 251:109–115
210. Flores-Borja, F., E. C., Jury, C., Mauri, and M. R., Ehrenstein. 2008. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA. 105:19396–19401
211. Nie, H., Y., Zheng, R., Li, et al. 2013. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis. Nat. Med. 19:322–328
212. Chang, H. C., S., Sehra, R., Goswami, et al. 2010. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat. Immunol. 11:527–534
213. Dardalhon, V., A., Awasthi, H., Kwon, et al. 2008. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat. Immunol. 9:1347–1355
214. Staudt, V., E., Bothur, M., Klein, et al. 2010. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity. 33:192–202
215. Veldhoen, M., C., Uyttenhove, J., van Snick, et al. 2008. Transforming growth factor-beta ‘reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat. Immunol. 9:1341–1346
216. Kaplan, M. H., N. L., Glosson, G. L., Stritesky, et al. 2011. STAT3-dependent IL-21 production from T helper cells regulates hematopoietic progenitor cell homeostasis. Blood. 117:6198–6201
217. Tan, C., M. K., Aziz, J. D., Lovaas, et al. 2010. Antigen-specific Th9 cells exhibit uniqueness in their kinetics of cytokine production and short retention at the inflammatory site. J. Immunol. 185:6795–6801
218. Zhao, P., X., Xiao, R. M., Ghobrial, and X. C., Li. 2013. IL-9 and Th9 cells:progress and challenges. Int. Immunolo. 25:547–551
219. Knoops, L., and J. C., Renauld. 2004. IL-9 and its receptor:from signal transduction to tumorigenesis. Growth Factors. 22:207–215
220. Kaplan, M. H., 2013. Th9 cells:differentiation and disease. Immunol. Rev. 252:104–115
221. Singh, T. P., M. P., Schön, K., Wallbrecht, et al. 2013. Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis. PLoS One. 8:e51752
222. Singh, T. P., B., Huettner, H., Koefeler, et al. 2011. Platelet-activating factor blockade inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.hTGF-β1 transgenic mice. Am. J. Pathol. 178:699–708
223. Schlapbach, C., A., Gehad, C., Yang, et al. 2014. Human TH9 cells are skin-tropic and have autocrine and paracrine proinflammatory capacity. Sci. Transl. Med. 6:219ra218
224. Nowak, E. C., C. T., Weaver, H., Turner, et al. 2009. IL-9 as a mediator of Th17-driven inflammatory disease. J. Exp. Med. 206:1653–1660
225. Elyaman, W., E. M., Bradshaw, C., Uyttenhove, et al. 2009. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc. Natl. Acad. Sci. USA. 106:12885–12890
226. Ma, L., H. B., Xue, X. H., Guan, et al. 2014. Possible pathogenic role of T helper type 9 cells and interleukin (IL)-9 in atopic dermatitis. J. Exp. Immunol. 175:25–31
227. Sismanopoulos, N., D. A., Delivanis, K. D., Alysandratos, et al. 2012. IL-9 induces VEGF secretion from human mast cells and IL-9/IL-9 receptor genes are overexpressed in atopic dermatitis. PLoS One. 7:e33271
228. Zibert, J. R., K., Wallbrecht, M., Schön, et al. 2011. Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions. J. Clin. Invest. 121:410–421
229. Karczewski, J., B., Poniedziałek, P., Rzymski, and Z., Adamski. 2014. Factors affecting response to biologic treatment in psoriasis. Dermatol. Ther. 27:323–330
230. Veldhoen, M., R. J., Hocking, C. J., Atkins, et al. 2006. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 24:179–189
231. Kleinewietfeld, M., and D. A., Hafler. 2013. The plasticity of human Treg and Th17 cells and its role in autoimmunity. Semin. Immunol. 25:305–312
232. Hirahara, K., A., Poholek, G., Vahedi, et al. 2013. Mechanisms underlying helper T-cell plasticity:implications for immune-mediated disease. J. Allergy Clin. Immunol. 131:1276–1287
233. Nakayamada, S., H., Takahashi, Y., Kanno, and J. J., O'Shea. 2012. Helper T cell diversity and plasticity. Curr. Opin. Immunol. 24:297–302
234. O'Shea, J. J., and W. E., Paul. 2010. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science. 327:1098–1102
235. Suárez-Fariñas, M., M. A., Lowes, L. C., Zaba, and J. G., Krueger. 2010. Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA). PLoS One. 5:e10247
236. Swindell, W. R., X., Xing, P. E., Stuart, et al. 2012. Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis. PLoS One. 7:e34594
237. Gudjonsson, J. E., J., Ding, A., Johnston, et al. 2010. Assessment of the psoriatic transcriptome in a large sample:additional regulated genes and comparisons with in vitro models. J. Invest. Dermatol. 130:1829–1840
238. Ainali, C., N., Valeyev, G., Perera, et al. 2012. Transcriptome classification reveals molecular subtypes in psoriasis. BMC Genomics. 13:472
239. Swindell, W. R., A., Johnston, J. J., Voorhees, et al. 2013. Dissecting the psoriasis transcriptome:inflammatory- and cytokine-driven gene expression in lesions from 163 patients. BMC Genomics. 14:527
240. Vasilopoulos, Y., M., Manolika, E., Zafiriou, et al. 2012. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol. Diagn. Ther. 16:29–34
241. Tejasvi, T., P. E., Stuart, V., Chandran, et al. 2012. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J. Invest. Dermatol. 132:593–600
242. Belasco, J., J. S., Louie, N., Gulati, et al. 2015. Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheumatol. 67:934–944
243. Mease, P. J., B. S., Goffe, J., Metz, et al. 2000. Etanercept in the treatment of psoriatic arthritis and psoriasis:a randomised trial. Lancet. 356:385–390
244. Mease, P. J., D. D., Gladman, C. T., Ritchlin, et al. 2005. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis:results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52:3279–3289
245. Papp, K. A., C., Leonardi, A., Menter, et al. 2012. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366:1181–1189
246. Leonardi, C., R., Matheson, C., Zachariae, et al. 2012. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366:1190–1199
247. Gottlieb, A., A., Menter, A., Mendelsohn, et al. 2009. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis:randomised, double-blind, placebo-controlled, crossover trial. Lancet. 373:633–640
248. Papp, K. A., R. G., Langley, B., Sigurgeirsson, et al. 2013. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis:a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br. J. Dermatol. 168:412–421
249. Mease, P. J., M. C., Genovese, M. W., Greenwald, et al. 2014. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N. Engl. J. Med. 370:2295–2306
250. de Souza, A., T., Ali-Shaw, S. M., Reddy, et al. 2013. Inflammatory arthritis following ustekinumab treatment for psoriasis:a report of two cases. Br. J. Dermatol. 168:210–212
251. Stamell, E. F., A., Kutner, K., Viola, and S. R., Cohen. 2013. Ustekinumab associated with flares of psoriatic arthritis. JAMA Dermatol. 149:1410–1413
252. Hughes, M., and H., Chinoy. 2013. Successful use of tocilizumab in a patient with psoriatic arthritis. Rheumatology (Oxford). 52:1728–1729
253. Ogata, A., N., Umegaki, I., Katayama, et al. 2012. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint, Bone, Spine Rev. Rheum. 79:85–87